Neurology and patient experience

What an Amyloid Result Means Before Alzheimer’s Symptoms

What AHEAD and SOKRATES found about learning an amyloid result before Alzheimer’s symptoms, and how trials can plan consent, disclosure and follow-up.

By Lampgen Clinical Research

An older adult speaks with a research coordinator across a table. The cover reads “Returning an amyloid result” and highlights consent, disclosure and follow-up in Alzheimer’s prevention trials.
AI-generated editorial illustration of a conversation about research results.

4 min read · estimated

Sources
3,414 adults80 interviews
AHEAD disclosure analysis and SOKRATES qualitative research

What the source reported

An amyloid PET scan can detect elevated brain amyloid in someone whose cognition remains intact. This lets researchers enroll participants earlier in Alzheimer’s prevention trials. It also asks people to consider the possibility of future cognitive decline while their thinking and daily function are still intact. An individual’s course remains uncertain after a single result. [1, 2]

Jason Karlawish’s November 6 STAT column asks what it is like to live with this information before symptoms appear. The SOKRATES study offers a window into that experience. Researchers interviewed 80 older adults screened for research, including 50 who learned they had elevated amyloid and 30 who learned they did not. Some in the elevated group reconsidered future plans or thought carefully about whom to tell because of stigma. Interviews capture what mattered to those participants. How often these experiences occur in the wider population remains an open question. [1, 3]

A 2026 analysis of 3,414 cognitively unimpaired adults screened for AHEAD measured distress 24 to 72 hours after disclosure. Everyone in the analysis had chosen to learn their APOE genetic result alongside their amyloid PET result. Higher-risk results were associated with higher scores for intrusive thoughts and avoidance, though group averages stayed below clinically significant thresholds. Amyloid results were associated with changes in perceived dementia risk. This observational study describes early reactions. The longer-term experience requires further follow-up. [4]

Earlier detection lets prevention trials test whether intervention can preserve cognition. In the Phase 3 A4 study, 1,169 cognitively unimpaired adults with elevated amyloid were randomized to solanezumab or placebo. Solanezumab did not slow cognitive decline on the trial’s primary composite measure over 240 weeks. AHEAD 3-45 is testing lecanemab in adults with intermediate or elevated amyloid. Changing a biomarker and preserving cognition are separate outcomes. [5, 6]

Research screening and clinical evaluation serve different populations. The Alzheimer’s Association’s 2025 blood-biomarker guideline applies to the diagnostic workup of people with objective cognitive impairment in specialized care. The Association workgroup’s 2024 criteria recommend limiting diagnostic testing of cognitively unimpaired individuals to research settings. [2, 7]

What this means for trial teams

Before testing. Explain which results the study may return, how they affect eligibility and what choices the participant has about receiving them. Confirm that approved materials are available in the participant’s preferred language. For a trial that returns both amyloid and APOE results, explain the difference between evidence of amyloid buildup and genetic information about risk. [8]

At disclosure. Have a qualified clinician explain the result and discuss uncertainty. Ask the participant to explain the result in their own words so the clinician can clarify misunderstandings. Invite a support person when the participant wants one and the protocol permits it. [8]

After disclosure. Give the participant a named contact and a plan for follow-up. Set a window for the check-in, assign who will make it, and define how a missed contact or a concerning response will be escalated. Agree on support for people who screen out, consistent with their consent and the protocol.

Track who can complete the process. Black adults accounted for 103 of 3,414 people (3%) in the AHEAD disclosure analysis. The researchers had too few participants in some groups to compare experiences by race, ethnicity or social determinants of health. Sponsors can plan interpreter access and transportation support early, then examine where participants encounter barriers between screening, disclosure and follow-up. [4]

Make responsibilities clear at site activation. The investigator oversees clinical interpretation and counseling. A CRA can verify that the site used the approved consent, assigned disclosure to qualified personnel and documented the required follow-up. The same division of responsibilities matters in biomarker-driven oncology studies when a molecular result changes eligibility or the next study visit.

If a prevention strategy preserves cognition in people without symptoms, more research programs and care teams may need to return results and support people over time. Preparing for that possibility means studying how well people understand their results and how their experience changes beyond the first few days.

Sources

  1. 1. STAT — Jason Karlawish on the experience of preclinical Alzheimer’s, November 6, 2026
  2. 2. Alzheimer’s & Dementia — 2024 revised criteria for diagnosis and staging of Alzheimer’s disease
  3. 3. PLOS ONE — SOKRATES interviews after amyloid PET result disclosure
  4. 4. JAMA Network Open — 2026 AHEAD amyloid and APOE disclosure analysis
  5. 5. New England Journal of Medicine — A4 trial of solanezumab
  6. 6. ClinicalTrials.gov — AHEAD 3-45, NCT04468659
  7. 7. Alzheimer’s Association — 2025 blood-based biomarker clinical practice guideline
  8. 8. Alzheimer’s Research & Therapy — Development of an amyloid result disclosure process

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?